Goldman Sachs Boosts Eli Lilly Price Target to $1,260, Citing 25% Growth
Goldman Sachs raised its price target on Eli Lilly to $1,260 from $1,145 and kept a Buy rating after the company beat expectations with Q4 EPS of $7.54 and $19.3B revenue. The bank projects 25% revenue growth in 2026 and highlights a Q2 launch of oral obesity pill orforglipron.
1. Price Target Raised on Strong Earnings
On February 5, Goldman Sachs raised its price target on Eli Lilly to $1,260 from $1,145 and reiterated a Buy rating after the company reported Q4 EPS of $7.54 and revenue of $19.3 billion, both exceeding consensus forecasts.
2. Bullish 2026 Guidance
Lilly projects full-year 2026 revenue of $80–83 billion and earnings of $33.50–35.00 per share, reflecting roughly 25% year-over-year top-line growth that surpasses analyst expectations of $77.62 billion.
3. Oral Obesity Pill Launch
Management highlighted a planned second-quarter U.S. launch of oral GLP-1 therapy orforglipron, with international rollouts in 2027, expecting limited cannibalization of injectable drugs and further expansion of the obesity treatment market.